DK1624878T3 - Anvendelse af præparater som omfatter en östrogen komponent til behandling og forebyggelse af muskel-skelet-smerte - Google Patents

Anvendelse af præparater som omfatter en östrogen komponent til behandling og forebyggelse af muskel-skelet-smerte

Info

Publication number
DK1624878T3
DK1624878T3 DK04734005T DK04734005T DK1624878T3 DK 1624878 T3 DK1624878 T3 DK 1624878T3 DK 04734005 T DK04734005 T DK 04734005T DK 04734005 T DK04734005 T DK 04734005T DK 1624878 T3 DK1624878 T3 DK 1624878T3
Authority
DK
Denmark
Prior art keywords
sub
estrogenic component
group
inhibitors
musculoskeletal pain
Prior art date
Application number
DK04734005T
Other languages
Danish (da)
English (en)
Inventor
Evert Johannes Bunschoten
Bennink Herman Jan Ti Coelingh
Original Assignee
Pantarhei Bioscience Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pantarhei Bioscience Bv filed Critical Pantarhei Bioscience Bv
Application granted granted Critical
Publication of DK1624878T3 publication Critical patent/DK1624878T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
DK04734005T 2003-05-22 2004-05-19 Anvendelse af præparater som omfatter en östrogen komponent til behandling og forebyggelse af muskel-skelet-smerte DK1624878T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03076555 2003-05-22

Publications (1)

Publication Number Publication Date
DK1624878T3 true DK1624878T3 (da) 2007-01-08

Family

ID=33462160

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04734005T DK1624878T3 (da) 2003-05-22 2004-05-19 Anvendelse af præparater som omfatter en östrogen komponent til behandling og forebyggelse af muskel-skelet-smerte

Country Status (13)

Country Link
US (1) US20060276414A1 (pt)
EP (1) EP1624878B1 (pt)
CN (1) CN100431545C (pt)
AT (1) ATE340580T1 (pt)
CA (1) CA2526338C (pt)
CY (1) CY1105766T1 (pt)
DE (1) DE602004002591T9 (pt)
DK (1) DK1624878T3 (pt)
ES (1) ES2274456T3 (pt)
PL (1) PL1624878T3 (pt)
PT (1) PT1624878E (pt)
SI (1) SI1624878T1 (pt)
WO (1) WO2004103377A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2299730T3 (es) * 2002-07-12 2008-06-01 Pantarhei Bioscience B.V. Composicion farmaceutica que comprende derivados de estetrol para el uso en la terapia del cancer.
US20080287408A1 (en) * 2007-05-14 2008-11-20 Drugtech Corporation Endometriosis treatment
KR20100068287A (ko) * 2007-09-17 2010-06-22 쁘레글렘 에스.아. 폐경기 전 여성의 에스트로겐 의존성 질환의 치료
DK2714712T3 (en) 2011-06-01 2016-12-05 Estetra Sprl A process for the preparation of intermediates estetrol
HUE029252T2 (en) 2011-06-01 2017-02-28 Estetra Sprl Process for the preparation of intermediates of estetrol
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
EP3936133A1 (en) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
RS61812B1 (sr) * 2015-06-18 2021-06-30 Estetra Sprl Oralno-disperzibilna tableta koja sadrži estetriol
AU2016280863B2 (en) 2015-06-18 2021-04-01 Estetra Srl Orodispersible dosage unit containing an estetrol component
KR102662025B1 (ko) 2015-06-18 2024-05-02 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 에스테트롤 성분을 함유하는 구강분해성 투여 단위
MD3310346T2 (ro) 2015-06-18 2021-06-30 Estetra Sprl Comprimată orodispersabilă ce conține estetrol
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
BR112018070199A2 (pt) 2016-04-01 2019-01-29 Therapeuticsmd Inc composição farmacêutica de hormônio esteroide
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
EP3787632B1 (en) 2018-05-02 2022-05-25 Estetra SPRL Treatment regimen for the treatment of advanced oestrogen receptor positive breast cancer

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2834712A (en) * 1953-05-27 1958-05-13 American Home Prod Urinary estrogen compositions and methods for preparing them
US2753290A (en) * 1953-08-06 1956-07-03 Olin Mathieson Microbiological production of 7-and 15-hydroxy-progesterones
US3440320A (en) * 1964-06-18 1969-04-22 Mortimer D Sackler Chelated suppository and method of using same
US3487152A (en) * 1967-02-07 1969-12-30 Hoffmann La Roche Tablets containing 7 - chloro - 2 - methylamino - 5 - phenyl - 3h - 1,4 - benzodiazepine-4-oxide and conjugated estrogenic substances
US3608075A (en) * 1969-07-28 1971-09-21 American Home Prod Compositions and methods of treating the menopausal syndrome
YU243975A (en) * 1974-10-14 1982-06-30 Schering Ag Process for obtaining 7-hydroxyestradiols
FR2377419A1 (fr) * 1977-01-13 1978-08-11 Roussel Uclaf Nouveaux derives steroides 11b-substitues 1,3,5 (10) trieniques, leur procede de preparation et leur application comme medicament
US4937238A (en) * 1986-03-04 1990-06-26 The Board Of Regents Of The University Of Nebraska Prevention of mammary carcinoma
US4762717A (en) * 1986-03-21 1988-08-09 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive
US5340586A (en) * 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
US5340585A (en) * 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
US5270172A (en) * 1991-04-26 1993-12-14 Dekk-Tek, Inc. Method to predict tumor response to therapy
US5468736A (en) * 1993-02-25 1995-11-21 The Medical College Of Hampton Road Hormone replacement therapy
US5811416A (en) * 1994-06-06 1998-09-22 Board Of Regents The University Of Texas System Endothelin antagonist and/or endothelin synthase inhibitor in combination with a progestin, an estrogen, a cyclooxygenase inhibitor, or a nitric acid donor or substrate
US6613757B1 (en) * 1994-09-22 2003-09-02 Board Of Regents, The University Of Texas System Combination of prostacyclin with an estrogen or progestin for the prevention and treatment of atherosclerotic vascular disease including preeclampsia and for the treatment of hypertension, and for hormone replacement therapy
US5672609A (en) * 1996-07-18 1997-09-30 Eli Lilly And Company Pyridine compounds, intermediates compositions and methods of use
US6170058B1 (en) * 1997-12-23 2001-01-02 Arcot Systems, Inc. Method and apparatus for cryptographically camouflaged cryptographic key storage, certification and use
US20010056068A1 (en) * 1998-03-04 2001-12-27 Kristof Chwalisz Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives
US6291456B1 (en) * 1998-12-30 2001-09-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US6117446A (en) * 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
GB0005257D0 (en) * 2000-03-03 2000-04-26 Pharmacia & Upjohn Spa Breast cancer hormonal therapy
RU2180570C1 (ru) * 2000-09-25 2002-03-20 Писаревский Юрий Леонидович Способ лечения болевого синдрома при дисфункциях височно-нижнечелюстного сустава у женщин
US6790979B2 (en) * 2002-04-17 2004-09-14 University Of North Carolina At Chapel Hill Curcumin analogues and uses thereof

Also Published As

Publication number Publication date
PL1624878T3 (pl) 2007-01-31
CA2526338C (en) 2012-09-25
WO2004103377A1 (en) 2004-12-02
EP1624878B1 (en) 2006-09-27
DE602004002591D1 (de) 2006-11-09
CY1105766T1 (el) 2011-02-02
PT1624878E (pt) 2007-01-31
SI1624878T1 (sl) 2007-02-28
DE602004002591T9 (de) 2008-01-03
ES2274456T3 (es) 2007-05-16
CN100431545C (zh) 2008-11-12
EP1624878A1 (en) 2006-02-15
CA2526338A1 (en) 2004-12-02
ATE340580T1 (de) 2006-10-15
CN1816340A (zh) 2006-08-09
US20060276414A1 (en) 2006-12-07
DE602004002591T2 (de) 2007-08-09

Similar Documents

Publication Publication Date Title
DK1624878T3 (da) Anvendelse af præparater som omfatter en östrogen komponent til behandling og forebyggelse af muskel-skelet-smerte
DK1446128T3 (da) Anvendelse af östrogenforbindelser i kombination med progestogenforbindelser i hormonsubstitutionsbehandling
WO2002094275A8 (en) Use of estrogen compounds to increase libido in women
HUP0203304A2 (hu) Prosztatarák megelőzésére szolgáló kemoterápiás módszer és készítmény
WO2001081310A8 (en) 1-aroyl-piperidinyl benzamidines
SG155967A1 (en) Hcv ns3-ns4a protease inhibition
NO20071264L (no) Cyklopaminanaloger og fremgangsmater for anvendelse derav.
UA98651C2 (ru) Спироциклы как ингибиторы 11-бета гидроксилстероиддегидрогеназы типа 1
NO20062679L (no) Nye 17 β -hydroksysteroid-dehydrogenase-type 1-inhibitorer
HUP0302067A2 (hu) Guanidinobenzamidszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
UA92348C2 (en) 17b-HSD1 AND STS INHIBITORS
BRPI0513184A (pt) derivados de 2-carbamida-4-feniltiazol, preparação dos mesmos e aplicação dos mesmos em terapia
TW200505411A (en) A formulation for chemical peeling
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
DE69918122D1 (de) Stabilisierung pharmazeutischer zusammensetzungen durch besonderen einsatz eines antioxidans
SG165314A1 (en) Imidazole derivatives as functionally selective alpha2c adrenoreceptor agonists
NO20091704L (no) Inhibitorer av hepatitt C virus
DK1758860T3 (da) Mættede og umættede 3-pyridylbenzocykloalkylmethylaminer til behandling af smerter, depressioner og angsttilstande
WO2004006936A8 (en) Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
IS7517A (is) Efnasambönd sem nýtast í meðferð við miltisbrandiog hindra banvænan þátt
AU2003274946A1 (en) Method of treating or preventing immune mediated disorders and pharmaceutical formulation for use therein
ATE443044T1 (de) Tace inhibitoren
BRPI0519006A2 (pt) uso de um inibidor de fbpase, kit de uma composiÇço farmacÊutica, uso de uma preparaÇço de biguanida e um inibidor de fbpase, agente terapÊutico para diabetes melito, e, combinaÇço de agentes terapÊuticos
DE602004018811D1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren